In the use of arsenic trioxide (ATO) for therapy in MM, high resistance to treatment has been reported, which is attributed in part to the activation of p38 mediated by ATO in cell lines and primary cultures of MM. This evidence concerns the gene MAPK14 and Miyoshi myopathy.